Bevacizumab in recurrent glioblastoma

Community Oncology

Volumn 6, Issue 9, 2009, Pages 397-399

  Stenger, Matt ^b   Altaha, Ramin ^a  

^a WEST VIRGINIA UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; CARBOPLATIN; CARMUSTINE; CILENGITIDE; DEXAMETHASONE; ERLOTINIB; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LOMUSTINE; OXALIPLATIN; PACLITAXEL; RAPAMYCIN; TAMOXIFEN; TEMOZOLOMIDE; TEMSIROLIMUS; VASCULOTROPIN A;

ADD ON THERAPY; BLEEDING; BREAST CANCER; BREAST CARCINOMA; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; COLON CARCINOMA; DEEP VEIN THROMBOSIS; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; EPISTAXIS; FATIGUE; GASTROINTESTINAL TOXICITY; GLIOBLASTOMA; GROUPS BY AGE; HUMAN; HYPERTENSION; INFECTION; KIDNEY CARCINOMA; LUNG CARCINOMA; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; METASTASIS; MONOTHERAPY; NEUTROPENIA; OVERALL SURVIVAL; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PROTEINURIA; RECOMMENDED DRUG DOSE; RECTUM CARCINOMA; RECURRENT CANCER; RETROPERITONEAL HEMORRHAGE; SHORT SURVEY; THROMBOEMBOLISM; TREATMENT OUTCOME; WOUND HEALING IMPAIRMENT;

EID: 70350450944     PISSN: 15485315     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1548-5315(11)70267-4     Document Type: Short Survey

References (5)

1. National Cancer Institute. FDA approval of bevacizumab. www.cancer.gov/cancertopics/druginfo/fda-bevacizumab. Accessed August 28, 2009.
2. FDA Briefing Document. Oncology Drug Advisory Committee Meeting. March 31, 2009. www.fda.gov/OHRMS/DOCKETS/ac/09/briefing/2009-4427b1-01-FDA. pdf. Accessed August 28, 2009.
3. Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009;27:740-745.
4. Vredenburgh JJ, Desjardins A, Herndon JE II, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007;25:4722-4729. (Pubitemid 350086473)
5. Nghiemphu PL, Liu W, Lee Y, et al. Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology 2009;72:1217-1222.